Advertisement
UK markets closed
  • FTSE 100

    8,433.76
    +52.41 (+0.63%)
     
  • FTSE 250

    20,645.38
    +114.08 (+0.56%)
     
  • AIM

    789.87
    +6.17 (+0.79%)
     
  • GBP/EUR

    1.1622
    +0.0011 (+0.09%)
     
  • GBP/USD

    1.2525
    +0.0001 (+0.01%)
     
  • Bitcoin GBP

    48,614.72
    -1,588.61 (-3.16%)
     
  • CMC Crypto 200

    1,259.42
    -98.59 (-7.26%)
     
  • S&P 500

    5,222.68
    +8.60 (+0.16%)
     
  • DOW

    39,512.84
    +125.08 (+0.32%)
     
  • CRUDE OIL

    78.20
    -1.06 (-1.34%)
     
  • GOLD FUTURES

    2,366.90
    +26.60 (+1.14%)
     
  • NIKKEI 225

    38,229.11
    +155.13 (+0.41%)
     
  • HANG SENG

    18,963.68
    +425.87 (+2.30%)
     
  • DAX

    18,772.85
    +86.25 (+0.46%)
     
  • CAC 40

    8,219.14
    +31.49 (+0.38%)
     

Global Endocrine Testing Market Report 2022: Increasing Prevalence of Endocrine-Related Disorders Fueling 7.89% CAGR

Company Logo
Company Logo

Global Endocrine Testing Market

Global Endocrine Testing Market
Global Endocrine Testing Market

Dublin, Sept. 13, 2022 (GLOBE NEWSWIRE) -- The "Endocrine Testing Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.

The global endocrine testing market size reached US$ 9.7 Billion in 2021. Looking forward, the publisher expects the market to reach US$ 15.3 Billion by 2027, exhibiting a CAGR of 7.89% during 2021-2027.

The increasing prevalence of endocrine-related disorders, such as adrenal insufficiency, Cushing's disease, gigantism, hypothyroidism and hyperthyroidism, represents one of the key factors driving the growth of the market.

ADVERTISEMENT

Furthermore, the increasing health consciousness and awareness regarding the benefits of timely testing is providing a boost to the market growth. Periodic testing minimizes the risks of developing complications or aggravation of the disorder, especially in elderly patients.

In line with this, the rising geriatric population is acting as another major growth-inducing factor. Moreover, due to the onset of the coronavirus (COVID-19) pandemic, endocrine testing is being widely used to detect hyperglycemia in infected patients.

Additionally, the development of innovative easy-to-operate test kits equipped with biosensors that facilitate user-friendly and cost-effective home-based diagnosis is creating a positive outlook for the market. Healthcare centers, laboratories and diagnostic centers are also using technologically advanced liquid chromatography with mass spectrometry (LC-MS) techniques to provide highly precise and accurate results.

Other factors, including improvements in the healthcare infrastructure, are anticipated to drive the market further.

Key Market Segmentation

Breakup by Test Type:

  • Thyroid Test

  • Insulin Test

  • Human Chorionic Gonadotropin Test

  • Prolactin Test

  • Luteinizing Hormone Test

  • Progesterone Test

  • Others

Breakup by Technology:

  • Immunoassay

  • Tandem Mass Spectroscopy

  • Sensor Technology

  • LC-MS

  • Others

Breakup by End Use:

  • Hospitals

  • Ambulatory Care Centers

  • Clinical Laboratories

  • Others

Breakup by Region:

  • North America

  • United States

  • Canada

  • Asia Pacific

  • China

  • Japan

  • India

  • South Korea

  • Australia

  • Indonesia

  • Others

  • Europe

  • Germany

  • France

  • United Kingdom

  • Italy

  • Spain

  • Russia

  • Others

  • Latin America

  • Brazil

  • Mexico

  • Others

  • Middle East and Africa

Key Topics Covered:

1 Preface

2 Scope and Methodology

3 Executive Summary

4 Introduction

5 Global Endocrine Testing Market

6 Market Breakup by Test Type

7 Market Breakup by Technology

8 Market Breakup by End Use

9 Market Breakup by Region

10 SWOT Analysis

11 Value Chain Analysis

12 Porters Five Forces Analysis

13 Price Analysis

14 Competitive Landscape

Companies Mentioned

  • Abbott Laboratories

  • Agilent Technologies Inc.

  • Bio-Rad Laboratories Inc.

  • BioMerieux SA

  • DiaSorin S.p.A.

  • F. Hoffmann-La Roche AG (Roche Holding AG)

  • Laboratory Corporation of America Holdings

  • Quest Diagnostics Incorporated

  • Siemens Healthineers AG (Siemens Aktiengesellschaft)

  • Thermo Fisher Scientific Inc.

For more information about this report visit https://www.researchandmarkets.com/r/bb8u82

Attachment

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900